CD19 and acquired polycythemia vera: Effects of anti CD19+ monoclonal antibodies (inebilizumab), which also act on plasma cells are studied in PV given that the production of anti-Dsg autoantibodies by LLPCs represents one of the mechanisms of rituximab resistance.